Article

4 Iconography
Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text
Advertising


Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates



Journal of the American Academy of Dermatology
Volume 74, n° 1
page 81 (janvier 2016)
Doi : 10.1016/j.jaad.2015.08.031
accepted : 13 August 2015
Original Articles

Prognostic markers in lentigo maligna patients treated with imiquimod cream: A long-term follow-up study
 

Mirja Gautschi, MD, Patrick A. Oberholzer, MD, Marc Baumgartner, MD, Karolina Gadaldi, MD, Nikhil Yawalkar, MD, Robert E. Hunger, MD, PhD
 Department of Dermatology, University of Bern, Bern, Switzerland 

Correspondence to: Robert E. Hunger, MD, PhD, Department of Dermatology, University of Bern, Inselspital, Freiburgstrasse 10, CH-3011 Bern, Switzerland.
Abstract
Background

More data are needed to define factors that predict long-term success after imiquimod therapy for lentigo maligna (LM).

Objective

We sought to determine the demographic, clinical, and histologic prognostic markers of relapse-free survival in patients with LM who were treated with imiquimod.

Methods

This was a single-arm, open-label, nonrandomized, prospective study.

Results

Eighty-nine patients with histologically confirmed LM and a median follow-up time of 4.8 years after imiquimod treatment were included in our study. Sixteen patients (18%) relapsed. Statistically significant indicators of an increased risk of local recurrence included: the total number of melanocytes, the number of basal and suprabasal melanocytes and the number of pagetoid spreading melanocytes.

Limitations

Our study was a single-center, nonrandomized study.

Conclusion

An assessment of different melanocyte fractions in the diagnostic baseline biopsy specimen may help to predict the response of LM to imiquimod therapy.

The full text of this article is available in PDF format.

Key words : efficacy, follow-up, imiquimod, lentigo maligna, prognostic marker, recurrence, topical immunomodulators



 Dr Gautschi and Dr Oberholzer contributed equally to this study.
 Funding sources: None.
 Conflicts of interest: None declared.



© 2015  American Academy of Dermatology, Inc.@@#104156@@
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Close
Article Outline